Large, Prospective Analysis of the Reasons Patients Do Not Pursue BRCA Genetic Testing Following Genetic Counseling by Hayden, Sommer et al.
ORIGINAL RESEARCH
Large, Prospective Analysis of the Reasons Patients
Do Not Pursue BRCA Genetic Testing Following Genetic
Counseling
Sommer Hayden1 & Sarah Mange2 & Debra Duquette2 & Nancie Petrucelli3 &
Victoria M. Raymond4 & on behalf of the BRCA Clinical Network Partners
Received: 11 January 2016 /Accepted: 29 December 2016 /Published online: 16 January 2017
# National Society of Genetic Counselors, Inc. 2017
Abstract Genetic counseling (GC) and genetic testing (GT)
identifies high-risk individuals who benefit from enhanced
medical management. Not all individuals undergo GT follow-
ing GC and understanding the reasons why can impact clinical
efficiency, reduce GT costs through appropriate identification
of high-risk individuals, and demonstrate the value of pre-GT
GC. A collaborative project sponsored by the Michigan
Department of Health and Human Services prospectively col-
lects anonymous data on BRCA-related GC visits performed
by providers in Michigan, including demographics, patient/
family cancer history, GT results, and reasons for declining
GT. From 2008 to 2012, 10,726 patients underwent GC; 3476
(32.4%) did not pursue GT. Primary reasons included: not the
best test candidate (28.1%), not clinically indicated (23.3%),
and insurance/out of pocket cost concerns (13.6%). Patient
disinterest was the primary reason for declining in 17.1%.
Insurance/out of pocket cost concerns were the primary reason
for not testing in 13.4% of untested individuals with private
insurance. Among untested individuals with breast and/or
ovarian cancer, 22.5% reported insurance/out of pocket cost
concerns as the primary reason for not testing and 6.6% failed
to meet Medicare criteria. In a five-year time period, nearly
one-third of patients who underwent BRCAGC did not pursue
GT. GTwas not indicated in almost half of patients. Insurance/
out of pocket cost concerns continue to be barriers.
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Introduction
Hereditary Breast and Ovarian Cancer due to germline muta-
tions in the tumor suppressor genes, BRCA1 (OMIM#113705)
and BRCA2 (OMIM#600185) is the most common inherited
breast and ovarian cancer condition and accounts for approx-
imately 7% of all breast cancer diagnoses (Claus et al. 1996;
Pal et al. 2005). Women with germline BRCA mutations have
an estimated 40–80% lifetime risk of breast cancer and an
estimated 11–44% risk of ovarian cancer (Chen and
Parmigiani 2007; Chen et al. 2006; King et al. 2003). The risk
of other cancers, including male breast cancer, pancreatic can-
cer, melanoma, and prostate cancer, are also elevated in indi-
viduals with germline BRCA mutations. Risk-reduction strat-
egies have proven beneficial in improving clinical outcomes,
thus demonstrating the importance of identifying high-risk
individuals (Domchek et al. 2006; Hartmann et al. 1999,
2001; Rebbeck et al. 2009; Saslow et al. 2007).
In the era of precision medicine, genetic counseling (GC)
and genetic testing (GT) can identify individuals with elevated
cancer risk for enrollment into these enhanced cancer surveil-
lance programs. Personal history of breast cancer, Ashkenazi
Jewish descent, strength of the family cancer history, heighted
personal risk perception, and desire for cancer risk informa-
tion are positively associated with patient uptake of GT
(Armstrong et al. 2000; Ropka et al. 2006). Although aware-
ness of the availability of BRCA GT continues to increase,
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women who are referred to GCmay not proceed with GT for a
variety of reasons (Borzekowski et al. 2014; Mai et al. 2014).
Previous studies have shown that affordability and insurance,
family concerns, fear of adverse psychological consequences,
logistic problems, and concerns regarding discrimination may
influence GT decisions (Armstrong et al. 2000; Godard et al.
2007; Kieran et al. 2007; Thompson et al. 2002). Factors
associated with GT uptake may also differ based on gender
and other demographic characteristics, such as education level
(Godard et al. 2007; Goelen et al. 1999; Hallowell et al. 2005;
Olaya et al. 2009; Thompson et al. 2002). Increasing demands
for GC, expanding insurance coverage for GT, federal and
state legislature to protect against GT discrimination, and in-
creasing awareness among patients and providers about the
benefits of GT has further evolved the field of clinical geno-
mics. In this new era, our current understanding of the reasons
individuals decline GT following GC is incomplete.
Expanding our understanding of the clinical, demographic,
and psychosocial factors impacting GT decision making is a
necessary component to the integration of GT into clinical
management, allowing for the ability to address potential bar-
riers, and identification of how GC professionals can adjust to
meet current demands. The current study uses a unique clini-
cal state database to collect and analyze the reasons individ-
uals did not pursue BRCA1 and BRCA2GT following GC and
risk assessment.
Materials and Methods
Data and Reporting
The Michigan Department of Health and Human Services
(MDHHS) developed a statewide surveillance network in-
cluding fifteen clinical facilities providing cancer GC to
Michigan patients by board-certified/board-eligible cancer ge-
netics providers. These facilities are located within the state,
with the exception of one out of state organization providing
GC services to Michigan patients by telephone. Participating
facilities prospectively report data for all patients receiving
BRCAGC, including demographics, patient and family cancer
history, and information derived during the GC and GT pro-
cess, including reasons for declining BRCA testing. These data
do not include patient names or identifiers.
Individuals seen for BRCA GC between January 1, 2008
and December 31, 2012 at a participating clinical facility were
included in the analysis. The status of undergoing a BRCA test
was defined as having any type of test (single site, Ashkenazi
founder mutation analysis, full sequencing and/or rearrange-
ment testing) at any time prior to, or after GC. BRCAGTstatus
was continuously updated in the database for a minimum of
nine months past the date of counseling, so that the tests of
patients who may have delayed testing for several months
were recorded.
Family cancer history was defined by the study team ac-
cording to the 2005 United States Preventive Services Task
Force (USPSTF) recommendation for GC referral (BGenetic
risk assessment and BRCA mutation testing for breast and
ovarian cancer susceptibility: recommendation statement.^
2005), the latest available USPSTF recommendation at the
time GC took place. High risk individuals were those who
met at least one of the following criteria: two first-degree
relatives with breast cancer, at least one of whom had breast
cancer at or before age 50; three or more first-or second-de-
gree relatives with breast cancer; a combination of both breast
and ovarian cancer among first- and second-degree relatives; a
first-degree relative with bilateral breast cancer; two or more
first- or second-degree relatives with ovarian cancer; a first- or
second-degree relative with both breast and ovarian cancer;
breast cancer in a male relative; Ashkenazi Jewish ancestry
and at least one first-degree relative with breast or ovarian
cancer; or Ashkenazi Jewish ancestry with at least two-
second degree relatives on the same side of the family with
breast and/or ovarian cancer. Personal and family cancer his-
tories and age of diagnoses were based on self-report at the
time of counseling, with possible verification through health
system records. The definition of breast cancer included ductal
carcinoma in situ.
Reasons for Not Testing
As part of the standard reporting process, at each visit the
genetics provider assigned the patient a single reason for not
testing according to a pre-determined menu of common rea-
sons. The menu options were designed through the expert
opinion of the genetic providers from the participating clinical
facilities (Table 2). For patients who did not test and were seen
for GC multiple times, the most recent reason for not testing
was used for analysis. Reasons for not testing were also
grouped by medically indicated reasons (testing was not clin-
ically indicated or that the patient was not the best test candi-
date in the family) and non-medically indicated reasons (in-
surance/out of pocket cost concerns, discuss options with rel-
atives, does not meet Medicare criteria, patient disinterest,
reassured by risk assessment, arrange life or disability insur-
ance, and Bother^) (Fig. 1, Table 3). BNot a good time^, ^does
not want to know ,^ and Bpatient sees no benefit^ indicated
patient decision not to test, thus these responses were com-
bined into the single Bpatient disinterest^ variable.
Some reasons were mutually exclusive. For instance, the
insurance/out of pocket cost concerns category includes both
uninsured and those who self-defined as having deductibles,
co-insurance, or co-pays that impeded testing. If a patient
failed to meet insurance criteria because of low risk, and the
provider did not believe GTwas indicated, the reason for not
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testing was considered to be that GT was not clinically indi-
cated rather than insurance/out of pocket cost concerns or not
meeting Medicare criteria. Similarly, the determination that
GT was not clinically indicated was made by the provider,
whereas the status of being reassured by the risk assessment
refers to the patient’s determination of clinical need.
Analysis
Frequencies and percentages were calculated to describe GT
patterns, reasons for not testing, and the demographic charac-
teristics of those with specific reasons for not testing.
Characteristics of those who had or did not have GT were
compared with chi-square tests. Post-hoc chi square testing
was conducted to examine test patterns among black versus
white patients and those with a personal history of breast and/
or ovarian cancer versus no personal history of cancer.
Insurance/out of pocket cost concerns as a barrier to GT was
examined by year from 2008 to 2012 with Cochran-Armitage
trend tests. All analyses were conducted using the SAS 9.3
statistical package.
These data are consistent with public health surveillance
and not research as defined by the code of federal regulations
(CFR) 46.102 (D) and therefore were deemed exempt by the
Michigan Department of Health and Human Services
(MDHHS) Institutional Review Board (IRB) for the
Protection of Human Research Subjects. The collaborative
project was reviewed by the IRB’s of each individual
institution.
Results
There were 10,726 patients who received BRCA-related GC
by a board-certified/eligible genetic counselor or geneticist in
the state ofMichigan between 2008 and 2012. The majority of
patients presenting for GC were female (N = 10,164; 94.8%)
and white (N = 8830; 82.3%); over half (N = 6000; 56.0%)
had a personal history of breast and/or ovarian cancer
(Table 1).
Approximately one-third (32.4%) of individuals did not have
BRCA GT after GC (Fig. 1, Table 1). In a comparison of black
versus white patients, black patients presenting for GC were
significantly less likely to have GT following GC than white
patients. 42.5% (N = 345) of black patients were not tested as
compared to 31.0% (N = 2740) of white patients (p < 0.01).
Nearly one-third of those who did not have GT had a per-
sonal history of breast and/or ovarian cancer; however, pa-
tients with cancer (breast and/or ovarian) were more likely to
have GT than those without a personal history of cancer
(p < 0.01). While 51.8% (N = 2450) of patients without a per-
sonal history of breast or ovarian cancer had BRCA testing,
79.5% (N = 4390) of those with breast cancer, 84.4%
(N = 314) of those with ovarian cancer, and 88.9% (N = 96)
of those with both breast and ovarian cancer had GT (Table 1).
Individuals presenting for GC with a known mutation in the
family comprised 12.2% (N = 6066) of patients counseled,
and 90.4% of these patients had testing compared to 64.4%
of those without a known family mutation (Table 1).
Reasons for not having a BRCA test were recorded for the
majority (N = 3314; 95.3%) of those without testing (Fig. 1).
The two most common reasons for not testing were that the
patient was not the best test candidate in the family (N = 930;
28.1%), and that testing was not clinically indicated (N = 773;
23.3%) (Table 2). Together these medical indications for not
testing accounted for over half (N = 1703; 51.4%) of those not
having testing. Examining those with medical indications for
not testing separately from those with non-medical reasons,
86.6% (N = 258) of individuals with breast cancer were not
clinically indicated for testing compared to 36.5% (N = 510)
of those without a cancer history (Table 3). However, more
than half (N = 889; 63.5%) of those without cancer were not
the best candidate for testing in the family (Table 3). Patients
with a high-risk family history were more frequently classified
as not being the best test candidate (N = 507; 78.0%), while
those without a family history were more frequently not clin-
ically indicated for testing (N = 630; 59.8%) (Table 3).
Insurance/out of pocket cost concern was the top non-
medical reason for not pursuing GT (N = 452; 28.1%)
(Table 3) Over one-third of individuals with insurance/out of
pocket cost concerns had a high-risk family history, and this
proportion did not significantly change over the duration of
the study. Individuals with private and government sponsored
insurance were equally likely to report insurance/out of pocket
10,726 individuals seen 
for BRCA1/2 genetic  
counseling
3,476 (32.4%) did not 
have testing
7,250 (67.6%) had a 
BRCA1/2 test 
162 without a recorded 
reason for not testing
(4.7%)
3,314 with a recorded 
reason for not testing
(95.3%)
1,703 with medically 
indicated reason for not  
testing (51.4%)
1,611 with non-medical 
reason for not testing 
(48.6%)
Fig. 1 Reasons for not testing among individuals seen for BRCA1/2
genetic counseling from January 1, 2008 to December 31, 2012
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cost concerns as a barrier to testing (N = 339; 13.4% and
N = 91; 13.7% respectively). In addition, 18% (N = 120) of
those with government-sponsored insurance did not test be-
cause they did not meet Medicare criteria.
All other reasons for not testing comprised less than ten
percent of patients who did not test (Table 2). Of note,
17.1% (N = 276) of non-medical abstinence from testing
could be attributed to patient disinterest (not a good time, does
not want to know, or patient sees no benefit), including 29.8%
(N = 28) of patients with a known family mutation who did
not test for non-medical reasons (Table 3). While only 1.7%
(N = 28) of patients with non-medical reasons cited a desire to
arrange life and/or disability insurance prior to GT, 10.6%
(N = 10) of patients with a known family mutation with non-
medical reasons cited this consideration (Table 3).
Discussion
With the increasing awareness of the availability of GT and
the impact of genomic information on medical management,
more individuals are presenting to their physicians and genet-
ics professionals for GT with questions about GT, and the
potential impact of GT results on personal medical care and
the care of family members. Specifically, individuals with
germline BRCA mutations are known to have elevated cancer
Table 1 Demographics and risk
factors of those with and without
subsequent BRCA testing after
genetic counseling, 2008-2012
Characteristic Did Not Test Tested Total Chi-square
p-value*
N (%) N (%) N (%)
Sex <0.01
Female 3324 (95.6) 6840 (94.3) 10,164 (94.8)
Male 152 (4.4) 410 (5.7) 562 (5.2)
Age <0.01
Age 50 or under 1844 (53.1) 3573 (49.3) 5417 (50.5)
Over 50 1632 (47.0) 3677 (50.7) 5309 (49.5)
Race <0.01
Asian 60 (1.7) 129 (1.8) 189 (1.8)
Black or African American 345 (9.9) 466 (6.4) 811 (7.6)
Other† 232 (6.7) 391 (5.4) 623 (5.8)
White 2740 (78.8) 6090 (84.0) 8830 (82.3)
Unknown 99 (2.9) 174 (2.4) 273 (2.6)
Insurance 0.45
Private 2671 (76.8) 5675 (78.3) 8346 (77.8)
Government sponsored 683 (19.7) 1374 (19.0) 2057 (19.2)
None 28 (0.8) 69 (1.0) 97 (0.9)
Unknown 94 (2.7) 132 (1.8) 226 (2.1)
Ashkenazi Jewish Ancestry <0.01
Yes 117 (3.4) 773 (10.7) 890 (8.3)
No 3359 (96.6) 6477 (89.3) 9836 (91.7)
Cancer History <0.01
Breast 1130 (32.5) 4390 (60.6) 5520 (51.5)
Ovarian 58 (1.7) 314 (4.3) 372 (3.5)
Both Breast and Ovarian 12 (0.4) 96 (1.3) 108 (1.0)
None 2276 (65.5) 2450 (33.8) 4726 (44.1)
High Risk Family History <0.01
Yes 1281 (36.9) 2978 (41.1) 4259 (39.7)
No 2195 (63.2) 4272 (58.9) 6467 (60.3)
Known Mutation in Family <0.01
Yes 126 (3.6) 1184 (16.3) 1310 (12.2)
No 3350 (96.4) 6066 (83.7) 9416 (87.8)
Total 3476 (32.4) 7250 (67.6) 10,726
*Chi-square statistic omitting missing or ‘unknown’ values
†includes all multiracial, Native Hawaiian or other Pacific Islander, American Indian or Alaska Native
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risks and established screening and surveillance guidelines
can reduce cancer related morbidity and mortality in this
high-risk population. However, it is known that the majority
of breast cancer and familial breast cancer is not due to
inherited germline mutations in BRCA1 and BRCA2 and
germline GT is not indicated in all individuals with personal
and/or family histories ofBRCA related cancer. Understanding
the reasons why individuals do not undergo GT following
cancer GC and genetic risk assessment may improve the iden-
tification of clinically appropriate GT candidates, aid in the
appropriate use of GC and GT resources, and ensure that each
patient receives appropriate screening and surveillance
recommendations based on their personal history, family his-
tory and if applicable, GT information.
Emerging data has identified substantial costs associated
with Binappropriate^ GT ordering practices (Lee 2013;
Miller et al. 2014). In our study, over a five-year time period,
approximately one-third of the 10,726 patients who
underwent BRCA GC did not pursue GT. In more than half
(51.4%) of these patients, GT was not indicated, either based
on risk assessment or because they were not the best test
candidate. This underscores the importance of GC and genetic
risk assessment to ensure appropriate clinical recommenda-
tions are provided to the patient and the family and for the
appropriate utilization of health care resources. GC for pa-
tients who meet referral criteria, but not GT criteria may be
beneficial for a variety of reasons. GC may lead to enhanced
awareness about the risk of an inherited cancer predisposition
syndrome and personal cancer risks, may provide patients
with reassurance, and may encourage communication with
appropriate relatives about their option to pursue GT.
The significant number of patients who were referred for
GC who did not undergo GT demonstrates the value of GC
prior to testing in order to aid in appropriate utilization of GT
andmedical resources. Understanding the reasonwhy individ-
uals did not pursue GT informs cost-savings initiatives and
also identifies educational needs for clinicians and patients.
Physician education regarding GT criteria and the importance
of initiating GT in the individual within the family with the
highest likelihood of carrying a germline mutation is a need
identified through this study. Future studies should examine in
more detail the exact reasons why GT was not clinically
Table 2 Primary reasons for not having BRCA testing after genetic
counseling
Reason Number (%)
Not the best test candidate 930 (28.1)
Not clinically indicated 773 (23.3)
Insurance/out of pocket cost concerns 452 (13.6)
Other reason 429 (12.9)
Discuss options with relatives 210 (6.3)
Does not meet Medicare criteria 133 (4.0)
Not a good time 133 (4.0)
Does not want to know 85 (2.6)
Reassured by risk assessment 83 (2.5)
Patient sees no benefit 58 (1.8)
Arrange life/disability insurance 28 (0.8)
Total 3314
Table 3 Reasons for not testing by personal and family cancer history, insurance status
Reasons for not Testing Total Personal Cancer History High Risk Family History Known Mutation
in Family
Breast Ovarian Breast &
Ovarian
None Yes No Yes No
Medically indicated reasons
Not the best test candidate 930 (54.6) 40 (13.4) 1 (16.7) – 889 (63.5) 507 (78.0) 423 (40.2) 12 (52.2) 918 (54.6)
Not clinically indicated 773 (45.4) 258 (86.6) 5 (83.3) – 510 (36.5) 143 (22.0) 630 (59.8) 11 (47.8) 762 (45.4)
Total 1703 298 6 – 1399 650 1053 23 1680
Non-medical reasons
Insurance/out of pocket cost concerns 452 (28.1) 247 (32.4) 15 (34.1) 5 (41.7) 185 (23.3) 138 (23.9) 314 (30.4) 7 (7.5) 445 (29.3)
Other reason 429 (26.6) 172 (22.6) 9 (20.5) 3 (25.0) 245 (30.9) 182 (31.5) 247 (23.9) 37 (39.4) 392 (25.8)
Patient disinteresta 276 (17.1) 149 (19.6) 7 (15.9) 3 (25.0) 117 (14.8) 92 (15.9) 184 (17.8) 28 (29.8) 248 (16.4)
Discuss options with relatives 210 (13.0) 79 (10.4) 8 (18.2) – 123 (15.5) 89 (15.4) 121 (11.7) 12 (12.8) 198 (13.1)
Does not meet Medicare criteria 133 (8.3) 74 (9.7) 4 (9.1) 1 (8.3) 54 (6.8) 43 (7.5) 90 (8.7) – 133 (8.7)
Reassured by risk assessment 83 (5.2) 36 (4.7) 1 (2.3) – 46 (5.8) 17 (3.0) 66 (6.4) – 83 (5.5)
Arrange life/disability insurance 28 (1.7) 5 (0.7) – – 23 (2.9) 16 (2.8) 12 (1.2) 10 (10.6) 18 (1.2)
Total 1611 762 44 12 793 577 1,034 94 1,517
a not a good time, does not want to know, and patient sees no benefit
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indicated in the 23.3% of the individuals who were not tested
and begin to develop resources for patients and clinicians to
better identify those who are at the highest risk.
Insurance/out of pocket cost concern continues to be a bar-
rier to appropriate GT, even for those affected with cancer and
those with private insurance. Of the 2214 people with private
insurance who did not pursue GT, the primary reason for de-
clining testing was insurance/out of pocket cost concerns
(15.3%). Insurance/out of pocket cost concerns was a barrier
for 36.4% of individuals with government sponsored insur-
ance. The American College of Medical Genetics and
Genomics recently published a policy statement challenging
payors and health care providers to expand their definition of
Bclinical utility^ and to increase the payor coverage of genetic
and genomic testing (BClinical utility of genetic and genomic
services: a position statement of the American College of
Medical Genetics and Genomics.^ 2015). The findings pre-
sented here underscore the need to increase coverage of GT
for those at elevated risk for hereditary cancer.
In 17.1% of the not tested cohort, 8.4% of the entire cohort
of patients who underwent GC, the reason for not testing was
Bpatient disinterest^. This category was comprised of Bdoes
not want to know ,^ Bnot a good time^, Bpatient sees no
benefit^. It is known that many factors can influence a pa-
tient’s decision to undergo GT including family concerns, fear
of adverse psychological consequences, logistic problems,
and concerns regarding discrimination as well as demographic
characteristics, such as gender and education level (Armstrong
et al. 2000; Godard et al. 2007; Goelen et al. 1999; Hallowell
et al. 2005; Kieran et al. 2007; Olaya et al. 2009; Thompson
et al. 2002). This is an area of future research need as we strive
to ensure we are providing patient centric care including ad-
dressing concerns and barriers to GT and understanding the
right time in a patient’s care to engage in a dialogue around
GT. These are likely to be based on individual preferences.
Future research should further study the needs of this group,
and will likely be most informative if combined with the co-
hort of patients who decline GC.
This study is not without its strengths and limitations. The
data collected are from genetics clinics that are supported by a
board certified/board eligible cancer genetics specialist. These
data may not be representative of the state as a whole and may
not reflect the practices and centers that offer GT in the ab-
sence of a certified professional. Additionally, each partner
clinic functions independently and uniquely. All partner
clinics are trained on data collection and all attempts to stan-
dardize reporting are made, however the primary reason why
an individual does not pursue GT is selected by the genetic
provider in each independent center. How each center and
each genetic provider identifies the primary reason may be
different and may not be consistent with the primary reason
a patient may select. Future studies should explore these lim-
itations. The study utilized a state-wide database,
encompassing all regions of the state of Michigan. The large
sample size allowed for ample collection of data on the rea-
sons for not pursuing GT. Providers were given the option to
free text write in if the reason was not one of the commonly
selected, permitting further flexibility in describing the clinical
scenario.
In summary, this study is the largest public health surveil-
lance program exploring BRCA GT in the United States. In
this large, prospective, multi-center study, nearly one-third of
patients did not pursue GT following GC and risk assessment.
The leading factors, GT was not clinically indicated and the
presenting individual was not the best person in whom to
initiate GT, highlight the value of GC and the importance of
a clinical genetics risk assessment prior to undergoing GT.
Additionally, insurance coverage and out of pocket cost con-
tinue to be barriers to GT, even in those with private insurance.
Continued understanding of the definition of Bclinical utility^
and demonstration of the multiple definitions of Bvalue^ in
GT can aid in addressing this GT barrier.
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